(...)... The deal covers the exclusive development and commercialisation rights for all oncology indications in China for PAT-SC1. Patrys will receive an upfront payment at that time and retains the right to develop and commercialise PAT-SC1 outside of China...(...)
on the other hand if you read that bit from Patrys website it says ALL oncology indications...so it may be leukemia? PAT-SC1 was for Gastric cancer and we had outstanding results (pure magic just about or miracle) and that is why I bought into it and loaded heaps (well, heaps for me).....lol...
wish they would hurry up with it...
Ann: Appendix 4C - Quarterly - 30 September 2017, page-15
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |